NASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Price, News & Analysis $15.40 -0.51 (-3.21%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$15.42 +0.01 (+0.10%) As of 07/8/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lyell Immunopharma Stock (NASDAQ:LYEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lyell Immunopharma alerts:Sign Up Key Stats Today's Range$14.70▼$16.8050-Day Range$11.61▼$21.4952-Week Range$9.02▼$45.00Volume270,591 shsAverage Volume246,460 shsMarket Capitalization$359.28 millionP/E RatioN/ADividend YieldN/APrice Target$43.00Consensus RatingModerate Buy Company Overview Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment. The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers. Early-stage candidates utilize technologies aimed at epigenetic reprogramming of T cells to improve their ability to expand, traffic to tumor sites and maintain durable anti-tumor activity. Lyell partners with academic centers and contract research organizations to advance its lead programs through IND-enabling studies and into clinical trials. Founded in 2017 and headquartered in South San Francisco, Lyell Immunopharma was established by a team of immunologists and cell therapy experts. The company has raised venture funding from leading life science investors and maintains research and manufacturing operations in the San Francisco Bay Area. Under the leadership of co-founder and CEO David Chang, Lyell is building a translational research engine designed to accelerate the discovery, development and manufacturing of engineered T cell products for patients with high-unmet-need cancers.AI Generated. May Contain Errors. Read More Lyell Immunopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreLYEL MarketRank™: Lyell Immunopharma scored higher than 74% of companies evaluated by MarketBeat, and ranked 135th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingLyell Immunopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialLyell Immunopharma has a consensus price target of $43.00, representing about 179.2% upside from its current price of $15.40.Amount of Analyst CoverageLyell Immunopharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lyell Immunopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lyell Immunopharma are expected to grow in the coming year, from ($7.87) to ($7.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lyell Immunopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.02% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 9.62.Change versus previous monthShort interest in Lyell Immunopharma has recently decreased by 2.71%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentLyell Immunopharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for LYEL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,573.00 in company stock.Percentage Held by Insiders6.20% of the stock of Lyell Immunopharma is held by insiders.Percentage Held by Institutions66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyell Immunopharma's insider trading history. Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYEL Stock News HeadlinesLyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 25, 2026 | globenewswire.comLyell Immunopharma Shareholders Back Governance at 2026 MeetingJune 15, 2026 | tipranks.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European ...June 14, 2026 | finance.yahoo.comNew Safety Data and Translational Findings for Ronde-cel in Relapsed or Refractory Large B-Cell Lymphoma Announced by Lyell ImmunopharmaJune 12, 2026 | quiverquant.comQLyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 CongressJune 12, 2026 | globenewswire.comInsider Selling: Lyell Immunopharma (NASDAQ:LYEL) Insider Sells 1,977 Shares of StockJune 12, 2026 | insidertrades.comLyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comSee More Headlines LYEL Stock Analysis - Frequently Asked Questions How have LYEL shares performed this year? Lyell Immunopharma's stock was trading at $30.78 at the start of the year. Since then, LYEL stock has decreased by 50.0% and is now trading at $15.40. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) released its earnings results on Wednesday, May, 6th. The company reported ($1.10) earnings per share for the quarter, meeting analysts' consensus estimates of ($1.10). The business earned $0 million during the quarter, compared to the consensus estimate of $0 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative trailing twelve-month return on equity of 85.71%. When did Lyell Immunopharma's stock split? Lyell Immunopharma's stock reverse split before market open on Friday, May 30th 2025.The 1-20 reverse split was announced on Friday, May 30th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Lyell Immunopharma IPO? Lyell Immunopharma (LYEL) raised $425 million in an initial public offering on Tuesday, June 15th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lyell Immunopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/06/2026Today7/08/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 LYEL's financial health is in the Yellow zone, according to TradeSmith. LYEL has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LYEL CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees270Year Founded2018Price Target and Rating Average Price Target for Lyell Immunopharma$43.00 High Price Target$49.00 Low Price Target$34.00 Potential Upside/Downside+179.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($13.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$274.45 million Net Margins-794,858.12% Pretax Margin-794,858.06% Return on Equity-85.71% Return on Assets-66.41% Debt Debt-to-Equity RatioN/A Current Ratio7.23 Quick Ratio7.23 Sales & Book Value Annual Sales$40 thousand Price / Sales8,982.05 Cash FlowN/A Price / Cash FlowN/A Book Value$11.68 per share Price / Book1.32Miscellaneous Outstanding Shares23,330,000Free Float21,887,000Market Cap$359.28 million OptionableOptionable Beta-0.06 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:LYEL) was last updated on 7/9/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LYEL Stock Alerts